CA1201988A - Lymphocytes destructeurs de cellules cancerigenes; methode pour les obtenir et agents anticancerigenes renfermant ces lymphocytes - Google Patents

Lymphocytes destructeurs de cellules cancerigenes; methode pour les obtenir et agents anticancerigenes renfermant ces lymphocytes

Info

Publication number: CA1201988A
Authority: CA; Canada
Prior art keywords: lectin; gra; glyco; cells; related antigen
Prior art date: 1981-10-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000406449A

Other languages

English (en)

Inventor

Masakazu Adachi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Otsuka Pharmaceutical Co Ltd

Original Assignee

Otsuka Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-10-01

Filing date

1982-06-30

Publication date

1986-03-18

1981-10-01 Priority claimed from JP56156413A external-priority patent/JPS5857318A/ja

1981-10-01 Priority claimed from JP15641481A external-priority patent/JPS5857321A/ja

1981-10-05 Priority claimed from JP56158472A external-priority patent/JPS5859922A/ja

1981-10-05 Priority claimed from JP56158473A external-priority patent/JPS5859923A/ja

1982-06-30 Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd

1986-03-18 Application granted granted Critical

1986-03-18 Publication of CA1201988A publication Critical patent/CA1201988A/fr

Status Expired legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 106
201000011510 cancer Diseases 0.000 title claims abstract description 92
238000000034 method Methods 0.000 title claims abstract description 68
230000008569 process Effects 0.000 title claims abstract description 30
238000004519 manufacturing process Methods 0.000 title claims abstract description 8
210000004698 lymphocyte Anatomy 0.000 title abstract description 41
239000002246 antineoplastic agent Substances 0.000 title abstract description 13
210000004027 cell Anatomy 0.000 claims abstract description 172
108090001090 Lectins Proteins 0.000 claims abstract description 53
102000004856 Lectins Human genes 0.000 claims abstract description 53
239000002523 lectin Substances 0.000 claims abstract description 53
239000000427 antigen Substances 0.000 claims abstract description 23
102000036639 antigens Human genes 0.000 claims abstract description 23
108091007433 antigens Proteins 0.000 claims abstract description 23
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims abstract description 14
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims abstract description 14
210000000170 cell membrane Anatomy 0.000 claims abstract description 13
229930182830 galactose Natural products 0.000 claims abstract description 10
239000000126 substance Substances 0.000 claims description 20
108010046016 Peanut Agglutinin Proteins 0.000 claims description 15
101710186708 Agglutinin Proteins 0.000 claims description 4
101710146024 Horcolin Proteins 0.000 claims description 4
244000112675 Lablab purpureus Species 0.000 claims description 4
101710189395 Lectin Proteins 0.000 claims description 4
101710179758 Mannose-specific lectin Proteins 0.000 claims description 4
101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 4
101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 4
239000000910 agglutinin Substances 0.000 claims description 4
239000012528 membrane Substances 0.000 claims description 3
108010048090 soybean lectin Proteins 0.000 claims description 3
241000220487 Bauhinia Species 0.000 claims description 2
108010058611 Helix lectin Proteins 0.000 claims description 2
244000046052 Phaseolus vulgaris Species 0.000 claims description 2
235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
240000000528 Ricinus communis Species 0.000 claims description 2
235000004443 Ricinus communis Nutrition 0.000 claims description 2
235000018907 Tylosema fassoglense Nutrition 0.000 claims description 2
238000000265 homogenisation Methods 0.000 claims description 2
238000005063 solubilization Methods 0.000 claims description 2
230000007928 solubilization Effects 0.000 claims description 2
108010084962 lima bean lectin Proteins 0.000 claims 1
239000004480 active ingredient Substances 0.000 abstract description 6
230000028993 immune response Effects 0.000 abstract description 6
229940041181 antineoplastic drug Drugs 0.000 abstract 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
241000699666 Mus <mouse, genus> Species 0.000 description 35
239000000872 buffer Substances 0.000 description 23
239000002609 medium Substances 0.000 description 21
102000004169 proteins and genes Human genes 0.000 description 21
108090000623 proteins and genes Proteins 0.000 description 21
239000011780 sodium chloride Substances 0.000 description 20
208000011691 Burkitt lymphomas Diseases 0.000 description 19
238000002360 preparation method Methods 0.000 description 17
238000001000 micrograph Methods 0.000 description 16
239000001963 growth medium Substances 0.000 description 15
238000012360 testing method Methods 0.000 description 15
239000012980 RPMI-1640 medium Substances 0.000 description 14
208000005718 Stomach Neoplasms Diseases 0.000 description 14
239000012636 effector Substances 0.000 description 14
206010017758 gastric cancer Diseases 0.000 description 14
210000004989 spleen cell Anatomy 0.000 description 14
201000011549 stomach cancer Diseases 0.000 description 14
230000003013 cytotoxicity Effects 0.000 description 13
231100000135 cytotoxicity Toxicity 0.000 description 13
229920002684 Sepharose Polymers 0.000 description 12
239000000203 mixture Substances 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 11
238000000926 separation method Methods 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
206010006187 Breast cancer Diseases 0.000 description 10
108010002350 Interleukin-2 Proteins 0.000 description 10
102000000588 Interleukin-2 Human genes 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
239000000243 solution Substances 0.000 description 10
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
-1 e.g. Substances 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
108010039433 dolichos biflorus agglutinin Proteins 0.000 description 8
239000007788 liquid Substances 0.000 description 8
239000002504 physiological saline solution Substances 0.000 description 8
210000000952 spleen Anatomy 0.000 description 8
208000026310 Breast neoplasm Diseases 0.000 description 7
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 7
238000001042 affinity chromatography Methods 0.000 description 7
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 7
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
206010070834 Sensitisation Diseases 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
210000000265 leukocyte Anatomy 0.000 description 6
230000008313 sensitization Effects 0.000 description 6
DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 6
244000068988 Glycine max Species 0.000 description 5
235000010469 Glycine max Nutrition 0.000 description 5
239000012981 Hank's balanced salt solution Substances 0.000 description 5
208000006552 Lewis Lung Carcinoma Diseases 0.000 description 5
206010058467 Lung neoplasm malignant Diseases 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
201000005202 lung cancer Diseases 0.000 description 5
208000020816 lung neoplasm Diseases 0.000 description 5
230000007505 plaque formation Effects 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
108010046569 Galectins Proteins 0.000 description 4
102000007563 Galectins Human genes 0.000 description 4
206010029260 Neuroblastoma Diseases 0.000 description 4
229920005654 Sephadex Polymers 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
230000027455 binding Effects 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
238000001502 gel electrophoresis Methods 0.000 description 4
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
230000002147 killing effect Effects 0.000 description 4
210000001165 lymph node Anatomy 0.000 description 4
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
238000010186 staining Methods 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
208000027930 type IV hypersensitivity disease Diseases 0.000 description 4
201000005112 urinary bladder cancer Diseases 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
201000009051 Embryonal Carcinoma Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
230000001093 anti-cancer Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000000306 component Substances 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
238000010586 diagram Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000005755 formation reaction Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
229960001375 lactose Drugs 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229960004857 mitomycin Drugs 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
229920000936 Agarose Polymers 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
235000010617 Phaseolus lunatus Nutrition 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
208000000389 T-cell leukemia Diseases 0.000 description 2
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
230000002308 calcification Effects 0.000 description 2
244000309466 calf Species 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000001311 chemical methods and process Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
150000002016 disaccharides Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
230000005484 gravity Effects 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229940102223 injectable solution Drugs 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229920001542 oligosaccharide Chemical group 0.000 description 2
150000002482 oligosaccharides Chemical group 0.000 description 2
108010086652 phytohemagglutinin-P Proteins 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
241000370685 Arge Species 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
240000003521 Bauhinia purpurea Species 0.000 description 1
235000011462 Bauhinia purpurea Nutrition 0.000 description 1
210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
244000045232 Canavalia ensiformis Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
VLHUSFYMPUDOEL-WZTVWXICSA-N Iothalamate meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VLHUSFYMPUDOEL-WZTVWXICSA-N 0.000 description 1
241000282564 Macaca fuscata Species 0.000 description 1
241000219822 Macrotyloma axillare Species 0.000 description 1
235000001504 Macrotyloma uniflorum var. uniflorum Nutrition 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
101000934342 Mus musculus T-cell surface glycoprotein CD5 Proteins 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
244000100170 Phaseolus lunatus Species 0.000 description 1
102000009097 Phosphorylases Human genes 0.000 description 1
108010073135 Phosphorylases Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002411 adverse Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
239000011324 bead Substances 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
230000005880 cancer cell killing Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
108010065337 fluorescein isothiocyanate-peanut agglutinin Proteins 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
HFZNPKDYLSOGBE-SCEMAYBHSA-N nrc-12 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(C)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)C(C)C)[C@@H](C)O)C(C)C)C(C)C)C1=CC=C(O)C=C1 HFZNPKDYLSOGBE-SCEMAYBHSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
229940116357 potassium thiocyanate Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000005951 type IV hypersensitivity Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA000406449A 1981-10-01 1982-06-30 Lymphocytes destructeurs de cellules cancerigenes; methode pour les obtenir et agents anticancerigenes renfermant ces lymphocytes Expired CA1201988A (fr)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
JP56156413A JPS5857318A (ja)	1981-10-01	1981-10-01	癌細胞障害性リンパ球の製造法
JP15641481A JPS5857321A (ja)	1981-10-01	1981-10-01	抗癌剤
JP156413/81		1981-10-01
JP156414/81		1981-10-01
JP158473/81		1981-10-05
JP158472/81		1981-10-05
JP56158472A JPS5859922A (ja)	1981-10-05	1981-10-05	癌細胞障害性リンパ球
JP56158473A JPS5859923A (ja)	1981-10-05	1981-10-05	抗癌剤

Publications (1)

Publication Number	Publication Date
CA1201988A true CA1201988A (fr)	1986-03-18

Family

ID=27473414

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000406449A Expired CA1201988A (fr)	1981-10-01	1982-06-30	Lymphocytes destructeurs de cellules cancerigenes; methode pour les obtenir et agents anticancerigenes renfermant ces lymphocytes

Country Status (3)

Country	Link
CA (1)	CA1201988A (fr)
ES (2)	ES8402615A1 (fr)
PH (1)	PH22474A (fr)

1982
- 1982-06-30 PH PH27516A patent/PH22474A/en unknown
- 1982-06-30 ES ES514450A patent/ES8402615A1/es not_active Expired
- 1982-06-30 CA CA000406449A patent/CA1201988A/fr not_active Expired
1983
- 1983-06-14 ES ES523253A patent/ES523253A0/es active Granted

Also Published As

Publication number	Publication date
ES8407392A1 (es)	1984-10-01
ES514450A0 (es)	1984-03-01
PH22474A (en)	1988-09-12
ES8402615A1 (es)	1984-03-01
ES523253A0 (es)	1984-10-01

Legal Events

Date	Code	Title	Description
2003-03-18	MKEX	Expiry

Publication	Publication Date	Title
Spits et al.	1982	Establishment of human T lymphocyte clones highly cytotoxic for an EBV-transformed B cell line in serum-free medium: isolation of clones that differ in phenotype and specificity.
JP7669434B2 (ja)	2025-04-28	がん治療のためのナチュラルキラー細胞および組成物の製造方法
EP0221748A2 (fr)	1987-05-13	Procédé de production d'anticorps humains
GB2106935A (en)	1983-04-20	Cancer cell-combatting lymphocytes process, for the production thereof, and anticancer agents containing said lymphocytes
AU632999B2 (en)	1993-01-21	Method and means for immuno-stimulating blood treatment with a mitogen
WO1999051720A2 (fr)	1999-10-14	Procedes de production de cytokines therapeutiques
EP0129173A2 (fr)	1984-12-27	Antigène associé à la malaria et son procédé de préparation
CN110540960A (zh)	2019-12-06	结合有免疫检查点阻断剂的t淋巴细胞及其在制备抗肿瘤药物中的应用
Wilson et al.	1987	Specific (EMT6) and non-specific (WEHI-164) cytolytic activity by host cells infiltrating tumour spheroids
FI80711C (fi)	1990-07-10	Foerfarande foer framstaellning av en terapeutiskt anvaendbar termiskt denaturerad, till en glykosidbindning ansluten antigen (gra), som haerroer sig fraon cancerceller.
NZ201112A (en)	1986-10-08	Preparation of a cancer-specific antigen and composition
WO1990004633A1 (fr)	1990-05-03	ACTIVATION ET CROISSANCE DE LYMPHOCYTES HUMAINS INFILTRANT LES TUMEURS AU MOYEN D'ANTICORPS ANTI-CD3 OU ANTI-TcR
EP0157427A2 (fr)	1985-10-09	Procédé de préparation d'un antigène apparenté à la liaison glycosidique
EP0254647A2 (fr)	1988-01-27	Médicaments pour le traitement de maladies auto-immunes
NZ214000A (en)	1986-10-08	Method of sensitising lymphocytes to cancer associated antigens
Reymond et al.	1975	Transfer factor preparations: some physico-chemical and biological properties
Shearer et al.	1977	Fractionation of lymphocytes involved in the generation of cell-mediated cytotoxicity over insolubilized conjugated histamine columns
KR880001758B1 (ko)	1988-09-12	암세포에 대항하는 임파구의 제조방법
US4772469A (en)	1988-09-20	Production of lymphoid tissue effector cells reactive against cancer cells by means of MER, and use thereof in cancer therapy
JPS591420A (ja)	1984-01-06	糖鎖関連抗原およびその製造法
SU1412596A3 (ru)	1988-07-23	Способ получени цитотоксических к раковым клеткам лимфоцитов и способ получени гликосв занного антигена
Bertini et al.	1974	A tumour-associated membrane antigen transiently expressed by normal cells during mitosis
NAKAJIMA et al.	1984	POLYSACCHARIDE, DMG, A DEGRADED D-MANNO-D-GLUCAN FROM MICROELLOBOSPORIA GRISEA CULTURE FLUID
US7309501B2 (en)	2007-12-18	Conditioned media to inhibit growth of tumor cells
Walsh et al.	1982	Inhibition of the lymphocyte blastogenic response to antigen by serum-free culture supernatants of leukemic B cells